Utilization of hematopoietic cell transplantation and cellular therapy technology in Europe and associated Countries. Using the 2022 activity survey data to correlate with economic and demographic factors. A report from the EBMT
We looked at treatment rates and center density across countries for patients treated in 2022; 46,143 HCTs (19,011 (41.2%) allogeneic, 27,132 (58.8%) autologous) reported by 689 centers. 4329 patients received advanced cellular therapies, 3205 were CAR-T. We found considerable differences in utilization of autologous, allogeneic HCT and more so for CAR-T. Differences in procedure type and for allogeneic HCT in donor use and disease indication are highlighted. For instance, countries with the highest use of unrelated donors per 10 million inhabitants were Germany (297) and the Netherlands (230), for identical sibling HCT it was Israel (148) and Lebanon (113), for haploidentical it was Israel (94) and Italy (94) and for cord blood it was the Netherlands (24) and the United Kingdom (15). We looked at HCT use for specific indications in allogeneic HCT (AML CR1, MDS, MPN and BMF). We correlated treatment rates with GNI and with demographic age structure and show correlations in HCT and CAR-T use and center density, highest in Italy for allogeneic and autologous HCT and in Switzerland for CAR-T. Resource restricted countries tend to concentrate HCT use in a limited number of centers. These data are useful for comparisons across countries.
Authors
- Jakob Robert Passweg (ORCID: https://orcid.org/0000-0001-7092-3351)
- Krzysztof Kałwak (ORCID: https://orcid.org/0000-0003-1174-5799)
- Donal P. McLornan (ORCID: https://orcid.org/0000-0003-1224-091X)
- Raffaella Greco (ORCID: https://orcid.org/0000-0002-6117-5328)
- Helen Baldomero (ORCID: https://orcid.org/0000-0002-6554-483X)
- John A. Snowden (ORCID: https://orcid.org/0000-0001-6819-3476)
- Fabio Ciceri (ORCID: https://orcid.org/0000-0003-0873-0123)
- Ali Bazarbachi (ORCID: https://orcid.org/0000-0002-7171-4997)
- Tobias Alexander (ORCID: https://orcid.org/0000-0003-1193-0097)
- Antonio M. Risitano (ORCID: https://orcid.org/0000-0002-4744-5109)
- Mette D. Hazenberg (ORCID: https://orcid.org/0000-0002-5113-0249)
- Diana Averbuch (ORCID: https://orcid.org/0000-0001-9614-7274)
- Emanuele Angelucci (ORCID: https://orcid.org/0000-0002-6512-6080)
- Anna Sureda (ORCID: https://orcid.org/0000-0002-1238-6970)
- Annalisa Ruggeri (ORCID: https://orcid.org/0000-0002-7261-2765)
Institutions
- University College London Hospitals NHS Foundation Trust (GB)
- Vita-Salute San Raffaele University (IT)
- Hebrew University of Jerusalem (IL)
- Hadassah Medical Center (IL)
- University Hospital of Basel (CH)
- Sanquin (NL)
- Wroclaw Medical University (PL)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Hospital Base (CL)
- Sheffield Teaching Hospitals NHS Foundation Trust (GB)
- Institut Català d'Oncologia (ES)
- Azienda Ospedaliera S.Giuseppe Moscati (IT)
- Ospedale Policlinico San Martino (IT)
- University College London (GB)
- Universitat de Barcelona (ES)
- Charité - Universitätsmedizin Berlin (DE)
- University of Amsterdam (NL)
- American University of Beirut (LB)
Publication Details
- Journal
- Bone Marrow Transplantation
- Published
- 2024-11-22
- DOI
- https://doi.org/10.1038/s41409-024-02459-0
- Citations
- 6
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- Universität Basel